Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 30;14(1):167.
doi: 10.1038/s41408-024-01150-3.

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Marie Hairing Enemark  1   2 , Jonas Klejs Hemmingsen  3 , Maja Dam Andersen  3   4 , Trine Engelbrecht Hybel  3   4 , Mads Emil Bjørn  5 , Pär Lars Josefsson  5 , Lars Møller Pedersen  6 , Maja Bech Juul  7 , Robert Schou Pedersen  8 , Michael Thorsgaard  9 , Ida Blok Sillesen  3 , Trine Lindhardt Plesner  10 , Stephen Jacques Hamilton-Dutoit  11 , Paw Jensen  12 , Charlotte Madsen  3 , Maja Ludvigsen  13   14
Affiliations

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Marie Hairing Enemark et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Overview of the study cohort.
*Not included if not registered in both the Danish Lymphoma Registry and the Danish Pathology Registry. The study cohort consisted of a total of 3,146 patients diagnosed with FL in Denmark between 2005–2020. From these, patients with data registered eligible for the POD24 analyses were identified, resulting in 2389 cases. Thus, the final study cohort consisted of 1836 POD24-neg patients and 553 POD24-pos patients. 3B-FL primary diagnosis of FL grade 3B, dc-tFL discordant/composite transformed FL, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, POD24 progression of disease within 24 months of diagnosis, nt-FL non-transforming FL, POD24-neg POD24-negative patients, POD24-pos POD24-positive patients, st-FL subsequently-transforming FL.
Fig. 2
Fig. 2. Risk factors and survival for POD24.
A Hazard ratios and forest plots comparing clinicopathological factors between POD24-neg and POD24-pos patients. Multivariate analysis was performed with imputated missing values under the assumption that data were missing at random. *Adjusted for risk factors not included in the FLIPI score. B Overall survival from a risk-defining event was defined as survival from time of a progressive event for POD24-pos patients and 24 months after treatment initiation for POD24-neg patients. C Progression-free survival in the POD24-neg patient group. β2m β2-microglobulin, BM bone marrow, CI confidence interval, FL follicular lymphoma, FLIPI follicular lymphoma international prognostic index, HR hazard ratio, LDH lactate dehydrogenase, NA not applicable, NS not significant, OS overall survival, PFS progression-free survival, POD24 progression of disease within 24 months from diagnosis, R rituximab.
See this image and copyright information in PMC

References

    1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95:316–27. - DOI - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Seibert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. - DOI - PMC - PubMed
    1. Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, et al. Follicular lymphoma. Nat Rev Dis Prim. 2019;5:83. - DOI - PubMed
    1. Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144–52. - DOI - PMC - PubMed
    1. Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99:1595–604. - DOI - PubMed

Publication types

LinkOut - more resources